Getting down to the numbers

The move means the pulmonary arterial hypertension drug is now available in the United States, Europe, and the United Kingdom.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

In a review of previous studies, researchers found that the images seen on social media contribute to taking actions that are both beneficial with patients seeking dermatological care and unfavorable with increased exposure to UV radiation for a better tan.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

The report also discusses the spurt of Stelera biosimilar approvals in late 2024.

Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD.